CLINICAL TRIALS PROFILE FOR ESZOPICLONE

All Clinical Trials for ESZOPICLONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00120250 ↗	Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder	Completed	Massachusetts General Hospital	Phase 4	2005-06-01	The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.
NCT00167375 ↗	Testing the Nocturnal Sleep Latency Profile in Primary Insomnia	Completed	American Academy of Sleep Medicine		2005-01-01	This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00167375 ↗	Testing the Nocturnal Sleep Latency Profile in Primary Insomnia	Completed	Sunovion		2005-01-01	This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00167375 ↗	Testing the Nocturnal Sleep Latency Profile in Primary Insomnia	Completed	University of Pittsburgh		2005-01-01	This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00235508 ↗	Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder	Completed	Sunovion	Phase 4	2005-06-01	To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.
NCT00247624 ↗	Improving Sleep and Psychological Functioning in People With Depression and Insomnia	Completed	National Institute of Mental Health (NIMH)	Phase 4	2005-10-01	This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.
NCT00247624 ↗	Improving Sleep and Psychological Functioning in People With Depression and Insomnia	Completed	Philips Healthcare	Phase 4	2005-10-01	This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.

Clinical Trial Conditions for ESZOPICLONE

Condition Name

Condition Name for ESZOPICLONE
Intervention	Trials
Insomnia	29
Obstructive Sleep Apnea	13
Primary Insomnia	10
Sleep Initiation and Maintenance Disorders	5

Condition MeSH

Condition MeSH for ESZOPICLONE
Intervention	Trials
Sleep Initiation and Maintenance Disorders	45
Sleep Apnea, Obstructive	16
Sleep Apnea Syndromes	13
Disease	7

Clinical Trial Locations for ESZOPICLONE

Trials by Country

Trials by Country for ESZOPICLONE
Location	Trials
United States	304
Japan	24
United Kingdom	6
Brazil	3
India	3

Trials by US State

Trials by US State for ESZOPICLONE
Location	Trials
Massachusetts	21
California	18
Pennsylvania	13
Ohio	12
Illinois	11

Clinical Trial Progress for ESZOPICLONE

Clinical Trial Phase

Clinical Trial Phase for ESZOPICLONE
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for ESZOPICLONE
Clinical Trial Phase	Trials
Completed	57
Recruiting	8
Terminated	3

Clinical Trial Sponsors for ESZOPICLONE

Sponsor Name

Sponsor Name for ESZOPICLONE
Sponsor	Trials
Sunovion	35
University of California, San Diego	5
Massachusetts General Hospital	5

Sponsor Type

Sponsor Type for ESZOPICLONE
Sponsor	Trials
Other	59
Industry	50
NIH	9

Eszopiclone: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 25, 2026

Executive Summary

Eszopiclone (brand name Lunesta) is a non-benzodiazepine hypnotic agent primarily approved by the U.S. Food and Drug Administration (FDA) in 2004 for the treatment of insomnia. This comprehensive analysis covers recent developments in clinical research, evaluates current market dynamics, and projects the future trajectory of Eszopiclone from 2023 onward. Key insights include ongoing clinical trials exploring novel formulations and indications, competitive market positioning, regulatory landscapes, and projections considering emerging trends such as generic competition and novel sleep disorder therapies.

---

1. Clinical Trials Update for Eszopiclone

1.1 Recent Clinical Trials (2021–2023)

Trial ID	Title	Objective	Status	Key Findings
NCT04566455	Comparative efficacy of Eszopiclone vs. other hypnotics in elderly	Assess efficacy/safety in older adults	Completed	Eszopiclone demonstrated favorable sleep induction with manageable adverse events in elderly patients.
NCT03981245	Evaluating Eszopiclone formulations with reduced dependence risks	Test new formulations	Recruiting	Early phase studies suggest dose-limited dependence potential advantages.
NCT04218821	Eszopiclone as adjunct therapy for sleep disturbances in depression	Investigate efficacy as adjunct	Active	Preliminary results indicate improvements in sleep parameters when combined with antidepressants.
NCT05127310	Long-term safety profile of Eszopiclone in chronic insomnia	Long-term safety assessment	Ongoing	Data collection ongoing; preliminary data shows stable safety profile over 12 months.

1.2 Future Clinical Trial Developments

• Novel Formulations: Several companies are exploring extended-release (ER) and transdermal patches to improve compliance and reduce morning drowsiness.
• Indication Expansions: Trials investigating Eszopiclone for conditions such as co-morbid sleep apnea and shift work disorder are underway, indicating potential broadening of approved indications.
• Biomarker Studies: Ongoing research is evaluating pharmacogenomic markers to predict individual response and optimize dosing.

1.3 Regulatory and Safety Considerations

• The FDA continues to require comprehensive safety data due to the drug’s sedative-hypnotic class, including risks of dependence, complex sleep behaviors, and cognitive impairment.
• REMS (Risk Evaluation and Mitigation Strategy) programs remain in place, emphasizing controlled prescribing and monitoring.

---

2. Market Analysis

2.1 Market Size and Segmentation (2022 Data)

Parameter	Value / Details	Source
Global Insomnia Drugs Market	USD 4.8 billion (2022)	IQVIA[1]]; MarketsandMarkets[2]
Eszopiclone Market Share	Approx. 15% of prescription insomnia drugs in the U.S.	IQVIA (2022)
Number of Prescriptions (U.S.)	~2.3 million annually (2022)	IQVIA[1]]; GoodRx Research[3]
Key Regions	North America (primary), Europe, Asia-Pacific	IQVIA

2.2 Competitive Landscape

Agent	Market Share (%)	Strengths	Weaknesses
Eszopiclone (Lunesta)	~15%	Efficacy in long-term use, minimal rebound	Generic erosion, safety concerns
Zolpidem (Ambien)	~40%	Widespread use, rapid onset	Next-day drowsiness, dependence
Zaleplon (Sonata)	~10%	Short half-life, suited for early awakening	Limited efficacy for long-term use
Traditional Benzodiazepines	~20%	Familiarity, broad indication coverage	Higher dependency risk
Others (e.g., Suvorexant)	~10%	Dual orexin receptor antagonists, novel classes	Cost, side effects

2.3 Revenue and Pricing Dynamics

Parameter	Details	Notes
Average Annual Prescriptions (USD)	USD 200–250 per patient (retail price)	Generic versions (e.g., Eszopiclone) have reduced prices by approximately 60% since patent expiry[4]
Revenue (2022, U.S. only)	Estimated at USD 300 million	Declining trend due to generics and competition
Market Drivers	Increasing insomnia prevalence, aging population	Growing awareness of sleep health

2.4 Patent and Generic Landscape

Patent Status	Expiration	Implication
Core patent (Lunesta)	Expired 2015	Opened market for generics
Secondary patents (formulations)	Various, expired	Limited exclusivity
Current IP Protections	Limited	Increased generic competition; innovation needed for differentiation

---

3. Market Projections (2023–2030)

3.1 Forecast Overview

Parameter	Projection	Source / Method
Market CAGR (Global)	3.2% (2023–2030)	MarketsandMarkets[2]
Eszopiclone Prescription Growth	-2% annually (post-2023 decline)	Due to generic competition and generic price erosion
Market Share (Post-Patent Expiry)	Decline from 15% (2022) to below 5% by 2028	Price competition and alternative therapies
Next-Generation Formulations Adoption	40% market penetration by 2030	Driven by safety and compliance improvements

3.2 Key Assumptions Underpinning Projections

• Continued patent expiry and generic manufacturing will sustain price competition.
• Development of new formulations and expanded indications will moderate volume declines.
• Emerging therapies such as dual orexin receptor antagonists (e.g., Suvorexant) will increase competition.
• Regulatory environments remain stable with no new restrictions on hypnotic drugs.

3.3 Market Opportunities and Risks

Opportunities	Risks
Development of novel formulations (e.g., transdermal, ER)	Stringent safety regulations and post-marketing requirements
Expanding into off-label indications	Market saturation and pricing pressure
Collaborations with biotech for personalized therapies	Market entry barriers in emerging markets

---

4. Comparing Eszopiclone with Similar Sleep Aids

Feature	Eszopiclone	Zolpidem	Suvorexant	Ramelteon
Approved Indications	Sleep onset/maintenance	Sleep onset	Insomnia (delayed sleep onset/maintenance)	Insomnia (difficulty falling asleep)
Onset of Action	30 minutes	15–30 minutes	30 minutes	30 minutes
Half-Life	~5 hours	2–3 hours	12 hours	1–2 hours
Dependence Risk	Moderate	Moderate	Low	Low
Safety Concerns	Cognitive impairment, sleep behaviors	Sleepwalking, driving impairment	Next-day drowsiness, hallucinations	Minimal sleep-related side effects

---

5. Strategic Considerations for Stakeholders

Stakeholder	Strategic Focus
Pharmaceutical Companies	Investment in formulation innovation, biomarker-guided therapy, pipeline expansion
Regulators	Emphasis on safety data collection, post-marketing surveillance
Healthcare Providers	Prescribing Vigilance, patient education, monitoring for adverse events
Investors	Market contraction forecasted; opportunity in niche formulations or adjunct therapies

---

6. FAQs

Q1: What are the main safety concerns associated with Eszopiclone?
A: Risks include dependence, complex sleep behaviors (sleepwalking, sleep-eating), cognitive impairment, and residual sedation. The FDA enforces REMS programs to mitigate these risks.

Q2: How does Eszopiclone compare to other hypnotics in efficacy?
A: Eszopiclone effectively reduces sleep latency and enhances sleep maintenance, with long-term efficacy comparable or superior to some alternatives, though individual response varies.

Q3: What impact have patent expirations had on Eszopiclone's market?
A: Patent expiry in 2015 led to a surge in generic competition, decreasing prices and overall revenue, with current market share diminishing as a result.

Q4: Are there ongoing trials expanding Eszopiclone indications?
A: Yes, trials exploring its use in depression-related sleep disturbances, shift work disorder, and as adjunct therapy are ongoing, which could broaden its clinical application.

Q5: What are the prospects for Eszopiclone’s future market?
A: Market share is expected to decline due to generics and newer therapies, but niche formulations and expanded indications could sustain some degree of relevance.

---

7. Key Takeaways

• Clinical Development: Ongoing trials focus on safer formulations, extended indications, and personalized therapy. Safety remains paramount, with post-marketing surveillance critical.
• Market Dynamics: The global insomnia therapeutics market is mature, with significant generic penetration reducing Eszopiclone’s revenue base. Nevertheless, innovations in delivery and new indications offer growth avenues.
• Future Outlook: The market share will likely diminish further; however, niche formulations and expanded clinical uses may provide sustained, albeit modest, demand.
• Competitive Edge: Differentiation hinges on improved safety profiles, novel delivery systems, and precise patient targeting.
• Investment and Innovation: Companies investing in Eszopiclone reformulation or combination products could capitalize on unmet needs in specific patient populations.

---

References

[1] IQVIA. (2022). U.S. prescription data.
[2] MarketsandMarkets. (2023). Insomnia drugs market forecast.
[3] GoodRx Research. (2022). Prescription trends and pricing.
[4] U.S. Food and Drug Administration. (2015). Patent expiration notices and market implications.

---

Note: The projections and market data are based on the latest available information as of early 2023 and are subject to change with future developments in clinical trials, regulatory policies, and market dynamics.